FDA Fast-Tracks New Oral Drug for Severe Asthma

Written by Ted Samson

Posted on May 26, 2026

Feel better informed on asthma and get real support from your community.

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to an experimental once-daily pill for moderate to severe eosinophilic asthma. The FDA’s fast-track program is designed to speed up the development and review of treatments for serious conditions when better options are needed.

The decision was based on early research suggesting that the drug, called KT-621, could help meet the need for more convenient and effective asthma therapies. The new treatment may be especially helpful for people whose symptoms are still hard to control with current therapies.

Many people with moderate to severe asthma use inhaled medications. Some may also need oral corticosteroids or injectable biologic drugs.

Share your thoughts.

🗳️ What type of treatment do you rely on most to manage your asthma?

Inhaled medications

Oral medications

Injectable biologic medication

Something else

What Is KT-621 and How Does It Work?

KT-621 belongs to a newer class of medicines called targeted protein degraders. The drug is designed to break down STAT6, a protein involved in signaling from interleukin (IL)-4 and IL-13. These immune system proteins contribute to type 2 inflammation, which is common in eosinophilic asthma.

Researchers say KT-621 works differently from injectable biologic drugs such as dupilumab. Biologics typically block inflammation outside cells, while KT-621 is designed to work inside cells by removing STAT6 itself. The goal is to reduce inflammation with a daily oral medication rather than injections.

Promising Early Trial Results

Preclinical studies and early-stage clinical trial results supported the FDA’s fast-track designation.

In an early study of people with atopic dermatitis (the most common type of eczema) who also had asthma, researchers reported lower levels of fractional exhaled nitric oxide (FeNO), a marker of airway inflammation. Participants also showed improved scores on asthma control questionnaires.

In another early trial involving healthy adults, KT-621 showed strong STAT6 degradation in blood and skin samples. Researchers also found lower levels of inflammatory biomarkers linked to IL-4 and IL-13 activity.

An ongoing clinical trial is studying KT-621 in about 264 adults with moderate to severe eosinophilic asthma. Researchers are evaluating changes in lung function over 12 weeks. Data from the study is expected in late 2027.

Reported Side Effects So Far

So far, reported side effects appear mostly mild. In one trial, researchers reported no serious or severe adverse events, no treatment-related discontinuations, and no clinically meaningful changes in laboratory tests or heart monitoring results.

Larger studies are still underway, and researchers will continue monitoring safety as more people receive the treatment.

Why This Matters for People With Eosinophilic Asthma

Biologic therapies have given people more asthma treatment options in recent years. Still, many people continue to have symptoms, flare-ups, or trouble managing multiple treatments.

If KT-621 proves safe and effective in larger studies, it could offer a new oral option for people with eosinophilic asthma.

The drug is still in early testing, so it isn’t available outside clinical trials. Results expected in late 2027 will help show whether the treatment moves into later-stage trials and possible FDA review.

If your asthma isn’t well controlled or you’re unhappy with your current treatment plan, talk with your healthcare provider about other treatment options and whether a clinical trial might be right for you.